The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 1, 2002, Pages 57-67

  Aarnoutse, Rob E ^a,b,c   Grintjes, Karin J T ^a,b,c   Telgt, Denise S C ^a,b,c   Stek Jr , Michael ^a,b,c   Hugen, Patricia W H ^a,b,c   Reiss, Peter ^a,b,c   Koopmans, Peter P ^a,b,c   Hekster, Yechiel A ^a,b,c   Burger, David M ^a,b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FATIGUE; FLUID INTAKE; FOOD INTAKE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SOMNOLENCE; STEADY STATE; VERTIGO;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; OXAZINES; RITONAVIR; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0036162141     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.121424     Document Type: Article

References (30)

1. Efavirenz
2. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection
3. Summary of product characteristics
4. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
5. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: A randomized, double-blind, placebo-controlled trial
6. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection
7. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
8. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice-daily dosing regimens in HIV-1-infected individuals
9. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in healthy volunteers
10. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: Pharmacokinetics, safety, and efficacy
11. Continued indinavir (800 mg tid) versus switching to indinavir + ritonavir (800/100 mg twice a day) in HIV patients having achieved viral load suppression: A randomized study - The BID efficacy and safety trial (BEST)
12. The electronic medication event monitor. Lessons for pharmacotherapy
13. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir by reversed-phase high-performance liquid chromatography
14. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography
15. Compartmental and noncompartmental pharmacokinetics
16. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
17. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
18. Pharmacokinetics of efavirenz and ritonavir after multiple oral doses in healthy volunteers
19. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients
20. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
21. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
22. Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HIV-positive patients
23. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
24. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir
25. Amprenavir (APV) plasma concentrations are dramatically increased by association to ritonavir (RTV) baby-doses in HIV-infected patients: Possible combination with efavirenz (EFV)
26. Study PROF 1004: Steady state pharmacokinetics of amprenavir 600 mg bid and ritonavir bid with or without NNRTI in HIV-1 infected patients
27. Amprenavir (APV) and ritonavir (RTV): Intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients
28. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir (ABT-378/r) and efavirenz (EFV) in healthy volunteers and in HIV+ subjects
29. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) with ritonavir (RTV) and efavirenz (EFV) combinations in a once-daily regimen in healthy volunteers (Merck 093)